Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 12 - Antimigraine Drugs

  • Eudenilson L. Albuquerque, Umberto L. Fulco, Ewerton W. S. Caetano, Valder N. Freire
  • Book:
    Quantum Chemistry Simulation of Biological Molecules
    Published online:
    21 January 2021
    Print publication:
    11 February 2021, pp 283-301

  • Summary

    Since the early days of migrainous research, serotonin receptors have been considered a major target of drugs, being among the most marketed one for its treatment. They are also involved in the mechanisms underlying many neurological dysfunctions. In this context, by taking advantage of their crystallographic structure co-crystallized with their agonist dihydroergotamine (DHE), one of the oldest and most widely used antimigraine drugs, a quantum chemistry study based on the electrostatically embedded molecular fractionation with conjugate caps scheme within the density functional theory formalism is performed to unveil this complex’s detailed binding energy. Furthermore, we predict the relevance of the DHE regions, as well as the influence of each protein segment to DHE–serotonin receptor binding. We believe that our work is a first step using in silico quantum design as a means to influence the discovery of new drugs to treat migraine and other diseases related to the serotonin agonist.